Back to Journals » Therapeutics and Clinical Risk Management » Volume 12

Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far

Authors Xu Y, Ding V, Zhang H, Zhang X, Jablons D, He B

Received 19 February 2016

Accepted for publication 4 May 2016

Published 24 May 2016 Volume 2016:12 Pages 807—816


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Garry Walsh

Yijun Xu,1,2 Vivianne W Ding,1 Hong Zhang,2 Xun Zhang,2 David Jablons,1 Biao He1

1Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA; 2Tianjin Chest Hospital, Tianjin, People’s Republic of China

Abstract: Compared to adenocarcinoma, fewer effective treatment options are available for advanced or metastatic squamous cell carcinoma (SCC) of the lung. Afatinib is an orally administered, irreversible EGFR antagonist. As a second-generation tyrosine kinase inhibitor, it has been applied in the treatment of patients with EGFR-mutant non-small-cell lung cancer. Recently, several clinical trials have shown that afatinib leads to a significant improvement in progression-free survival and overall survival of patients with SCC. Moving forward, afatinib should be one of the options among tyrosine kinase inhibitors, monoclonal antibodies, and cytotoxicity chemotherapy drugs for SCC.

Keywords: afatinib, squamous cell carcinoma, EGFR, tyrosine kinase inhibitor, non-small-cell lung cancer, ErbB

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]